First Time Loading...

Concert Pharmaceuticals Inc
NASDAQ:CNCE

Watchlist Manager
Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Watchlist
Price: 8.37 USD
Updated: Mar 28, 2024

Intrinsic Value

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of CNCE.

Key Points:
CNCE Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Concert Pharmaceuticals Inc's business.

What risks and challenges
does Concert Pharmaceuticals Inc face in the near future?

Summarize the latest earnings report
of Concert Pharmaceuticals Inc.

Provide P/E
for Concert Pharmaceuticals Inc and its competitors.

Financials

Balance Sheet Decomposition
Concert Pharmaceuticals Inc

Current Assets 157.2m
Cash & Short-Term Investments 149.5m
Receivables 1.6m
Other Current Assets 6m
Non-Current Assets 13.9m
PP&E 12.8m
Other Non-Current Assets 1.2m
Current Liabilities 17.4m
Accounts Payable 2.7m
Accrued Liabilities 4.7m
Other Current Liabilities 9.9m
Non-Current Liabilities 20.5m
Other Non-Current Liabilities 20.5m
Efficiency

Earnings Waterfall
Concert Pharmaceuticals Inc

Revenue
42k USD
Operating Expenses
-160.3m USD
Operating Income
-160.3m USD
Other Expenses
-3.7m USD
Net Income
-164m USD

Free Cash Flow Analysis
Concert Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CNCE Profitability Score
Profitability Due Diligence

Concert Pharmaceuticals Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
13/100
Profitability
Score

Concert Pharmaceuticals Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

CNCE Solvency Score
Solvency Due Diligence

Concert Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Concert Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CNCE Price Targets Summary
Concert Pharmaceuticals Inc

There are no price targets for CNCE.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CNCE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CNCE Price
Concert Pharmaceuticals Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
+69%
5Y 5Y
-34%
10Y 10Y
-32%
Annual Price Range
8.37
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return -20.9%
Standard Deviation of Annual Returns 55.92%
Max Drawdown -79%
Shares Statistics
Market Capitalization 401.2m USD
Shares Outstanding 48 022 600
Percentage of Shares Shorted 2.43%

CNCE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

401.2m USD

Dividend Yield

0%

Description

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Contact

MASSACHUSETTS
Lexington
65 Hayden Ave Ste 3000N
+17818600045.0
https://www.concertpharma.com/

IPO

2014-02-13

Employees

64

Officers

Co-Founder & Independent Chairman
Mr. Richard H. Aldrich M.B.A., Mba
Co-Founder, CEO, Pres & Exec. Director
Dr. Roger D. Tung Ph.D.
Chief Financial Officer
Mr. Marc A. Becker
Chief Devel. Officer
Dr. James V. Cassella Ph.D.
Chief Operating Officer
Ms. Nancy Stuart
Sr. VP of Corp. Communications & Investor Relations
Ms. Justine E. Koenigsberg
Show More
Chief Legal Officer & Corp. Sec.
Mr. Jeffrey A. Munsie
VP of Corp. Devel.
Dr. Nabil Uddin Pharm.D.
Sr. VP of Regulatory Affairs & Quality Assurance
Ms. Christine Boisclair
Show Less

See Also

Discover More